PTC Therapeutics (PTCT) Financials

$47.86 +1.93 (+4.20%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$46.36 -1.50 (-3.13%)

As of 04:30 AM Eastern

Annual Income Statements for PTC Therapeutics

This table shows PTC Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-363	-627	-559	-524	-438	-252	-128	-79	-142	-170
Consolidated Net Income / (Loss)	-363	-627	-559	-524	-438	-252	-128	-79	-142	-170
Net Income / (Loss) Continuing Operations	-363	-627	-559	-524	-438	-252	-128	-79	-142	-170
Total Pre-Tax Income	-363	-696	-587	-518	-403	-240	-128	-78	-142	-170
Total Operating Income	-303	-440	-447	-374	-432	-241	-116	-64	-132	-167
Total Gross Profit	749	938	654	506	362	295	252	190	83	37
Total Revenue	807	938	699	539	381	307	265	194	83	37
Operating Revenue	807	938	699	539	381	307	265	194	83	37
Total Cost of Revenue	57	0.00	45	32	19	12	13	4.58	0.00	0.00
Operating Cost of Revenue	57	-	45	32	19	12	13	4.58	-	0.00
Total Operating Expenses	1,052	1,377	1,102	881	794	536	368	254	215	204
Selling, General & Admin Expense	301	333	326	286	245	203	154	121	97	82
Research & Development Expense	534	667	651	541	478	257	172	117	118	122
Amortization Expense	61	223	117	55	37	28	23	15	0.00	0.00
Other Operating Expenses / (Income)	-4.48	-128	-26	-0.50	34	48	19	0.00	0.00	-
Impairment Charge	160	218	33	0.00	0.00	-	-	-	-	-
Total Other Income / (Expense), net	-61	-257	-140	-144	29	1.23	-12	-13	-9.48	-2.83
Interest Expense	0.00	138	0.00	0.00	-	-	-	-	-	-
Interest & Investment Income	-67	-129	-91	-86	-56	-12	-13	-12	-8.28	-2.37
Other Income / (Expense), net	6.54	10	-49	-58	85	14	0.13	-1.28	-1.21	-0.47
Income Tax Expense	0.18	-70	-28	5.56	35	12	-0.03	1.34	0.57	0.49
Basic Earnings per Share	($4.73)	($8.37)	($7.79)	($7.43)	($6.64)	($4.27)	($2.75)	($2.02)	($4.17)	($5.07)
Weighted Average Basic Shares Outstanding	76.85M	74.84M	71.73M	70.47M	66.03M	58.86M	46.58M	39.18M	34.04M	33.63M
Diluted Earnings per Share	($4.73)	($8.37)	($7.79)	($7.43)	($6.64)	($4.27)	($2.75)	($2.02)	($4.17)	($5.07)
Weighted Average Diluted Shares Outstanding	76.85M	74.84M	71.73M	70.47M	66.03M	58.86M	46.58M	39.18M	34.04M	33.63M
Weighted Average Basic & Diluted Shares Outstanding	78.87M	76.61M	73.82M	71.36M	66.03M	58.86M	46.58M	39.18M	34.04M	33.63M

This table shows PTC Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	867	-66	-107	-99	-92	-156	-133	-199	-139	-171	-109
Consolidated Net Income / (Loss)	867	-66	-107	-99	-92	-156	-133	-199	-139	-171	-109
Net Income / (Loss) Continuing Operations	867	-66	-107	-99	-92	-156	-133	-199	-139	-171	-109
Total Pre-Tax Income	930	-95	-98	-86	-85	-157	-167	-237	-135	-190	-127
Total Operating Income	970	-162	-55	-40	-45	5.82	-118	-210	-118	-200	-68
Total Gross Profit	1,163	156	197	187	210	343	187	201	206	143	217
Total Revenue	1,176	213	197	187	210	307	197	214	220	167	217
Operating Revenue	1,176	213	197	187	210	307	197	214	220	167	217
Total Cost of Revenue	13	57	0.00	0.00	0.00	-36	9.49	13	14	25	0.00
Operating Cost of Revenue	13	-	-	-	-	-	9.49	13	14	-	-
Total Operating Expenses	193	318	251	227	256	338	305	411	324	343	285
Selling, General & Admin Expense	81	85	73	70	73	76	81	88	87	93	80
Research & Development Expense	109	125	161	132	116	121	164	186	195	189	165
Amortization Expense	3.80	3.31	3.04	2.87	52	77	59	47	39	36	31
Other Operating Expenses / (Income)	-0.80	-10	0.70	5.10	-0.10	-2.70	1.50	-129	2.40	6.30	-5.30
Impairment Charge	0.08	-	1.84	1.76	-	-	0.00	218	-	-	0.00
Total Other Income / (Expense), net	-40	68	-43	-46	-39	-163	-48	-28	-17	11	-59
Interest Expense	0.00	-	0.00	0.00	0.00	138	0.00	0.00	0.00	-	-
Interest & Investment Income	-34	59	-42	-43	-41	-44	-28	-29	-27	-25	-21
Other Income / (Expense), net	-6.31	8.85	-1.87	-2.03	1.59	19	-20	1.48	9.96	35	-38
Income Tax Expense	63	-29	8.66	13	6.88	-1.26	-34	-39	3.97	-19	-18
Basic Earnings per Share	$11.09	($0.85)	($1.39)	($1.29)	($1.20)	($2.07)	($1.76)	($2.66)	($1.88)	($2.35)	($1.53)
Weighted Average Basic Shares Outstanding	78.12M	76.85M	76.93M	76.73M	76.50M	74.84M	75.38M	74.73M	73.73M	71.73M	71.65M
Diluted Earnings per Share	$10.04	($0.85)	($1.39)	($1.29)	($1.20)	($2.07)	($1.76)	($2.66)	($1.88)	($2.35)	($1.53)
Weighted Average Diluted Shares Outstanding	86.39M	76.85M	76.93M	76.73M	76.50M	74.84M	75.38M	74.73M	73.73M	71.73M	71.65M
Weighted Average Basic & Diluted Shares Outstanding	79.26M	78.87M	77.13M	76.92M	76.70M	76.61M	75.46M	75.34M	74.19M	73.82M	71.88M

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	185	314	99	-19	-79	126	58	53	0.30	8.27
Net Cash From Operating Activities	-108	-158	-357	-251	-194	-99	-28	-10	-104	-124
Net Cash From Continuing Operating Activities	-108	-158	-357	-251	-194	-99	-28	-10	-104	-124
Net Income / (Loss) Continuing Operations	-363	-627	-559	-524	-438	-252	-128	-79	-142	-170
Consolidated Net Income / (Loss)	-363	-627	-559	-524	-438	-252	-128	-79	-142	-170
Depreciation Expense	76	237	129	64	43	32	26	18	3.29	2.88
Amortization Expense	-11	-0.33	3.61	7.15	43	-1.23	0.09	0.97	2.19	2.59
Non-Cash Adjustments To Reconcile Net Income	151	411	225	225	92	44	41	37	42	36
Changes in Operating Assets and Liabilities, net	40	-179	-155	-24	66	78	34	13	-9.16	4.70
Net Cash From Investing Activities	44	-177	290	219	-562	-387	-43	13	104	-21
Net Cash From Continuing Investing Activities	44	-177	290	219	-562	-387	-43	13	104	-21
Purchase of Property, Plant & Equipment	-6.50	-28	-32	-28	-18	-14	-7.10	-3.10	-1.78	-2.72
Acquisitions	-68	-92	-120	-57	-38	-36	-57	-77	0.00	0.00
Purchase of Investments	-667	-212	-76	-543	-1,440	-494	-69	-81	-85	-224
Sale of Property, Plant & Equipment	28	0.00	0.00	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	598	156	518	848	944	156	90	175	192	206
Other Investing Activities, net	160	0.00	0.00	-	-10	0.00	-	-	-	-
Net Cash From Financing Activities	256	646	168	21	669	613	132	44	0.97	154
Net Cash From Continuing Financing Activities	256	646	168	21	669	613	132	44	0.97	154
Repayment of Debt	0.00	-382	-161	0.00	-29	-12	0.00	-0.43	0.00	-
Issuance of Debt	0.00	0.00	300	0.00	0.00	279	0.00	40	0.00	150
Issuance of Common Equity	5.20	5.95	56	5.79	33	327	121	2.47	0.00	0.00
Other Financing Activities, net	251	1,023	-27	15	664	18	11	2.18	0.97	4.06
Effect of Exchange Rate Changes	-7.33	3.11	-2.77	-7.82	7.69	-1.30	-3.61	6.20	-1.58	-0.64
Cash Interest Paid	5.82	36	18	9.59	9.80	7.69	7.77	6.27	4.51	0.00
Cash Income Taxes Paid	18	14	4.92	7.71	26	2.11	1.58	1.10	0.94	0.11

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	701	256	-129	104	-46	429	-43	-9.10	-62	175	-54
Net Cash From Operating Activities	870	-30	-77	-71	71	-100	-15	-14	-29	-166	-38
Net Cash From Continuing Operating Activities	870	-30	-77	-71	71	-100	-15	-14	-29	-166	-38
Net Income / (Loss) Continuing Operations	867	-66	-107	-99	-92	-156	-133	-199	-139	-171	-109
Consolidated Net Income / (Loss)	867	-66	-107	-99	-92	-156	-133	-199	-139	-171	-109
Depreciation Expense	7.22	6.76	6.49	7.02	55	81	62	51	43	39	34
Amortization Expense	-2.01	-2.28	-2.65	-3.00	-3.40	-1.81	0.57	0.56	0.35	0.51	0.63
Non-Cash Adjustments To Reconcile Net Income	41	61	15	30	45	58	47	281	25	24	78
Changes in Operating Assets and Liabilities, net	-43	-30	11	-6.08	65	-81	9.00	-147	41	-59	-42
Net Cash From Investing Activities	-184	268	-43	-66	-115	-94	-30	-24	-29	32	136
Net Cash From Continuing Investing Activities	-184	268	-43	-66	-115	-94	-30	-24	-29	32	136
Purchase of Property, Plant & Equipment	-1.72	-3.77	-0.52	7.38	-9.59	-5.57	-6.36	-6.25	-10	-8.62	-5.38
Acquisitions	-0.81	-2.73	-10	-	-55	-23	-23	-13	-33	-18	-21
Purchase of Investments	-328	-141	-217	-196	-113	-186	-8.22	-18	0.00	-12	-23
Sale of Property, Plant & Equipment	0.07	-	0.02	-	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	146	265	175	94	63	120	7.83	14	15	72	185
Net Cash From Financing Activities	9.41	26	-18	246	0.54	620	3.36	18	4.09	303	-140
Net Cash From Continuing Financing Activities	9.41	26	-18	246	0.54	620	3.36	18	4.09	303	-140
Other Financing Activities, net	9.41	23	-18	245	0.54	1,000	3.45	15	4.28	-39	10
Effect of Exchange Rate Changes	5.39	-8.65	8.54	-5.19	-2.03	3.10	-2.33	10	-7.96	6.02	-12
Cash Interest Paid	2.16	-	2.16	-	3.67	2.11	12	9.35	13	5.78	4.41
Cash Income Taxes Paid	3.04	4.77	6.66	4.08	2.04	0.52	4.44	6.98	2.22	0.89	1.08

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	1,705	1,896	1,706	1,938	2,208	1,624	1,119	392	269	365
Total Current Assets	1,366	1,219	694	954	1,232	779	321	249	261	356
Cash & Equivalents	780	594	280	190	209	288	-	112	58	58
Short-Term Investments	360	283	131	584	895	399	58	79	173	281
Accounts Receivable	159	161	156	110	70	56	68	40	25	11
Inventories, net	23	31	22	16	19	19	16	11	0.00	-
Prepaid Expenses	44	150	106	55	39	18	9.25	6.67	4.69	5.93
Plant, Property, & Equipment, net	61	87	73	53	34	22	13	8.38	7.43	8.97
Total Noncurrent Assets	279	590	939	931	943	823	786	134	0.63	0.36
Goodwill	82	82	82	82	82	82	82	0.00	-	-
Intangible Assets	119	379	706	725	715	711	701	133	0.00	-
Other Noncurrent Operating Assets	77	128	151	124	145	30	2.30	1.22	0.63	0.36
Total Liabilities & Shareholders' Equity	1,705	1,896	1,706	1,938	2,208	1,624	1,119	392	269	365
Total Liabilities	2,803	2,714	2,053	1,937	1,726	1,029	768	235	150	139
Total Current Liabilities	581	603	406	509	277	236	167	82	50	45
Accounts Payable	304	392	320	289	242	159	128	76	49	45
Current Deferred Revenue	5.51	0.80	1.35	0.00	4.15	8.24	3.72	3.94	0.00	0.14
Other Current Liabilities	271	210	85	71	31	48	23	1.67	0.87	0.00
Total Noncurrent Liabilities	2,222	2,111	1,646	1,427	1,449	794	602	153	100	94
Long-Term Debt	285	284	572	282	309	294	141	145	98	92
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	56	103	137	137	131	122	0.00	-	-
Other Noncurrent Operating Liabilities	1,937	1,771	972	1,008	1,003	365	329	0.24	0.34	2.05
Total Equity & Noncontrolling Interests	-1,098	-819	-347	1.44	482	594	351	156	120	226
Total Preferred & Common Equity	-1,098	-819	-347	1.44	482	594	351	156	120	226
Total Common Equity	-1,098	-819	-347	1.44	482	594	351	156	120	226
Common Stock	2,575	2,466	2,305	2,124	2,172	1,795	1,288	967	856	820
Retained Earnings	-3,647	-3,284	-2,657	-2,098	-1,629	-1,190	-939	-814	-735	-593
Accumulated Other Comprehensive Income / (Loss)	-26	-1.29	4.80	-24	-61	-11	1.46	3.97	-1.49	-1.20

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	2,655	1,842	1,916	1,790	1,260	1,338	1,609	1,576
Total Current Assets	2,316	1,282	1,358	1,169	540	590	613	517
Cash & Equivalents	1,480	526	655	548	165	208	167	104
Short-Term Investments	547	487	439	336	130	130	119	184
Accounts Receivable	210	200	187	198	166	178	202	124
Inventories, net	22	36	32	30	36	32	27	15
Prepaid Expenses	57	33	46	56	44	42	99	90
Plant, Property, & Equipment, net	59	63	66	93	85	82	79	67
Total Noncurrent Assets	280	498	492	528	634	666	916	992
Goodwill	82	82	82	82	82	82	82	82
Intangible Assets	118	330	330	330	423	452	686	750
Other Noncurrent Operating Assets	79	85	80	116	129	132	147	160
Total Liabilities & Shareholders' Equity	2,655	1,842	1,916	1,790	1,260	1,338	1,609	1,576
Total Liabilities	2,841	2,897	2,897	2,684	1,931	1,917	2,066	1,803
Total Current Liabilities	595	611	610	575	492	476	442	420
Accounts Payable	318	336	339	331	371	359	332	329
Current Deferred Revenue	13	0.00	0.00	0.00	1.22	0.00	0.21	-
Other Current Liabilities	265	274	271	244	120	118	109	91
Total Noncurrent Liabilities	2,246	2,286	2,287	2,109	1,439	1,441	1,625	1,383
Long-Term Debt	286	285	285	285	573	573	572	283
Other Noncurrent Operating Liabilities	1,960	1,945	1,946	1,769	813	816	950	963
Total Equity & Noncontrolling Interests	-186	-1,054	-980	-894	-671	-579	-458	-227
Total Preferred & Common Equity	-186	-1,054	-980	-894	-671	-579	-458	-227
Total Common Equity	-186	-1,054	-980	-894	-671	-579	-458	-227
Common Stock	2,609	2,531	2,511	2,487	2,447	2,417	2,340	2,223
Retained Earnings	-2,780	-3,581	-3,474	-3,375	-3,128	-2,995	-2,796	-2,486
Accumulated Other Comprehensive Income / (Loss)	-14	-4.34	-16	-5.56	9.61	-1.43	-1.59	36

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-13.97%	34.20%	29.75%	41.45%	24.04%	15.96%	36.19%	135.04%	124.95%	45.64%
EBITDA Growth	-19.98%	46.97%	-0.87%	-38.71%	-32.47%	-119.83%	-90.49%	63.28%	21.18%	-69.27%
EBIT Growth	31.06%	13.54%	-14.87%	-24.74%	-52.39%	-96.82%	-76.23%	50.80%	20.48%	-68.22%
NOPAT Growth	31.16%	1.77%	-19.49%	13.28%	-79.04%	-108.46%	-79.94%	51.32%	20.98%	-68.12%
Net Income Growth	42.02%	-12.09%	-6.70%	-19.57%	-74.17%	-96.42%	-62.13%	44.41%	16.63%	-81.80%
EPS Growth	43.49%	-7.45%	-4.85%	-11.90%	-55.50%	-55.27%	-36.14%	51.56%	17.75%	-70.71%
Operating Cash Flow Growth	32.02%	55.58%	-41.91%	-29.51%	-96.75%	-256.86%	-174.68%	90.28%	16.71%	-117.09%
Free Cash Flow Firm Growth	-64.08%	296.18%	-99.73%	-200.96%	302.93%	53.73%	-46.11%	-69.63%	11.57%	-92.00%
Invested Capital Growth	-38.36%	-658.36%	45.35%	-8.95%	-241.01%	-19.75%	150.68%	894.42%	34.20%	-25.65%
Revenue Q/Q Growth	-10.42%	17.50%	0.31%	-11.80%	58.68%	26.19%	-14.61%	37.33%	17.73%	0.21%
EBITDA Q/Q Growth	-1,201.73%	54.31%	-9.06%	-164.54%	41.09%	-10.65%	-102.86%	42.58%	15.25%	-10.44%
EBIT Q/Q Growth	-151.50%	30.67%	-10.97%	-115.24%	33.80%	-10.21%	-66.22%	31.28%	15.18%	-10.87%
NOPAT Q/Q Growth	-125.19%	31.93%	-34.84%	-60.50%	23.03%	-15.98%	-63.68%	32.14%	14.95%	-10.57%
Net Income Q/Q Growth	19.84%	2.35%	-5.20%	-73.36%	26.27%	-16.12%	-52.36%	26.21%	14.53%	-16.13%
EPS Q/Q Growth	20.50%	3.24%	-4.28%	-15.73%	2.21%	-3.64%	-67.68%	30.10%	14.90%	-21.88%
Operating Cash Flow Q/Q Growth	39.49%	29.31%	-37.42%	-1.81%	-38.71%	4.77%	-414.46%	77.47%	14.11%	-21.90%
Free Cash Flow Firm Q/Q Growth	-74.58%	414.05%	-40.97%	-47.86%	14.51%	9.34%	-13.59%	14.45%	6.22%	-7.60%
Invested Capital Q/Q Growth	-9.52%	-259.56%	20.00%	-2.54%	4.45%	-17.34%	-3.98%	-7.94%	-19.52%	-129.79%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	92.89%	100.00%	93.61%	94.00%	95.03%	96.05%	95.21%	97.65%	100.00%	100.00%
EBITDA Margin	-28.72%	-20.59%	-52.11%	-67.03%	-68.36%	-64.01%	-33.76%	-24.14%	-154.51%	-440.98%
Operating Margin	-37.50%	-46.86%	-64.03%	-69.52%	-113.39%	-78.56%	-43.70%	-33.07%	-159.67%	-454.58%
EBIT Margin	-36.69%	-45.78%	-71.07%	-80.27%	-91.02%	-74.09%	-43.65%	-33.73%	-161.13%	-455.84%
Profit (Net Income) Margin	-45.03%	-66.81%	-80.00%	-97.27%	-115.07%	-81.95%	-48.38%	-40.64%	-171.83%	-463.60%
Tax Burden Percent	100.05%	90.02%	95.15%	101.07%	108.74%	104.86%	99.98%	101.72%	100.40%	100.29%
Interest Burden Percent	122.66%	162.12%	118.30%	119.90%	116.26%	105.49%	110.86%	118.44%	106.21%	101.41%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-67.83%	-41.92%	-93.47%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-30.82%	36.03%	-55.64%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	14.58%	-8.58%	36.23%	0.00%	0.00%
Return on Equity (ROE)	37.91%	107.51%	323.46%	-216.75%	-81.42%	-53.24%	-50.51%	-57.24%	-82.24%	-65.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-45.92%	-127.86%	-153.44%	0.00%	0.00%
Operating Return on Assets (OROA)	-16.44%	-23.85%	-27.26%	-20.85%	-18.09%	-16.58%	-15.30%	-19.84%	-42.00%	-47.99%
Return on Assets (ROA)	-20.18%	-34.80%	-30.68%	-25.27%	-22.87%	-18.34%	-16.95%	-23.90%	-44.79%	-48.80%
Return on Common Equity (ROCE)	37.91%	107.51%	323.46%	-216.75%	-81.42%	-53.24%	-50.51%	-57.24%	-82.24%	-65.00%
Return on Equity Simple (ROE_SIMPLE)	33.08%	76.55%	161.06%	0.00%	-90.91%	-42.33%	-36.52%	-50.50%	-118.84%	-75.42%
Net Operating Profit after Tax (NOPAT)	-212	-308	-313	-262	-302	-169	-81	-45	-92	-117
NOPAT Margin	-26.25%	-32.80%	-44.82%	-48.67%	-79.38%	-54.99%	-30.59%	-23.15%	-111.77%	-318.20%
Net Nonoperating Expense Percent (NNEP)	-20.94%	-147.83%	-271.75%	-46.07%	-23.29%	-37.01%	-77.95%	-37.83%	-26.11%	-19.01%
Return On Investment Capital (ROIC_SIMPLE)	26.06%	57.58%	-139.42%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	7.11%	0.00%	6.39%	6.00%	4.97%	3.95%	4.79%	2.35%	0.00%	0.00%
SG&A Expenses to Revenue	37.30%	35.46%	46.65%	53.06%	64.39%	65.98%	58.00%	62.38%	117.44%	223.25%
R&D to Revenue	66.25%	71.08%	93.23%	100.39%	125.44%	83.87%	64.96%	60.42%	142.23%	331.33%
Operating Expenses to Revenue	130.39%	146.86%	157.63%	163.52%	208.42%	174.61%	138.91%	130.72%	259.67%	554.58%
Earnings before Interest and Taxes (EBIT)	-296	-429	-497	-432	-347	-227	-116	-66	-133	-168
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-232	-193	-364	-361	-260	-196	-89	-47	-128	-162
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	1,958.20	8.64	4.98	4.94	4.42	3.13	4.91
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.52	3.13	4.91
Price to Revenue (P/Rev)	4.32	2.22	3.93	5.23	10.94	9.64	6.54	3.56	4.53	30.20
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	11.67	6.00	5.86	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.26	1.59	4.16	4.59	8.85	8.43	6.26	3.32	2.91	23.48
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	7.97	1.62	0.00	0.00	14.53	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.26	-0.35	-1.65	300.02	0.64	0.53	0.44	0.93	0.82	0.41
Long-Term Debt to Equity	-0.26	-0.35	-1.65	196.03	0.64	0.49	0.40	0.93	0.82	0.41
Financial Leverage	0.75	0.37	0.52	-2.35	-1.08	-0.47	-0.24	-0.65	-1.10	-1.07
Leverage Ratio	-1.88	-3.09	-10.54	8.58	3.56	2.90	2.98	2.39	1.84	1.33
Compound Leverage Factor	-2.30	-5.01	-12.47	10.28	4.14	3.06	3.30	2.84	1.95	1.35
Debt to Total Capital	-35.12%	-53.19%	254.51%	99.67%	39.08%	34.56%	30.38%	48.10%	45.09%	28.90%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	34.55%	0.00%	2.20%	2.32%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-35.12%	-53.19%	254.51%	65.12%	39.08%	32.36%	28.06%	48.10%	45.09%	28.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	135.12%	153.19%	-154.51%	0.33%	60.92%	65.44%	69.62%	51.90%	54.91%	71.10%
Debt to EBITDA	-1.23	-1.47	-1.57	-1.20	-1.19	-1.60	-1.71	-3.09	-0.77	-0.57
Net Debt to EBITDA	3.69	3.07	-0.44	0.95	3.05	1.90	0.83	0.99	1.04	1.52
Long-Term Debt to EBITDA	-1.23	-1.47	-1.57	-0.78	-1.19	-1.50	-1.58	-3.09	-0.77	-0.57
Debt to NOPAT	-1.35	-0.92	-1.83	-1.65	-1.02	-1.86	-1.89	-3.22	-1.06	-0.79
Net Debt to NOPAT	4.03	1.93	-0.51	1.30	2.63	2.21	0.92	1.03	1.44	2.11
Long-Term Debt to NOPAT	-1.35	-0.92	-1.83	-1.08	-1.02	-1.74	-1.75	-3.22	-1.06	-0.79
Altman Z-Score	-1.80	-1.83	-1.73	-0.83	0.59	0.83	0.24	-0.69	-2.70	2.12
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.35	2.02	1.71	1.87	4.44	3.30	1.92	3.04	5.27	7.84
Quick Ratio	2.23	1.72	1.39	1.74	4.23	3.15	0.76	2.82	5.17	7.71
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	329	917	-468	-234	232	-114	-247	-169	-100	-113
Operating Cash Flow to CapEx	0.00%	-557.06%	-1,113.99%	-890.84%	-1,087.66%	-717.01%	-389.47%	-324.51%	-5,831.42%	-4,571.21%
Free Cash Flow to Firm to Interest Expense	0.00	6.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-1.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-1.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.52	0.38	0.26	0.20	0.22	0.35	0.59	0.26	0.11
Accounts Receivable Turnover	5.05	5.93	5.25	5.97	6.07	4.97	4.89	5.95	4.59	4.73
Inventory Turnover	2.13	0.00	2.37	1.87	1.00	0.69	0.94	0.00	0.00	0.00
Fixed Asset Turnover	10.90	11.75	11.17	12.47	13.75	17.93	25.13	24.60	10.08	4.06
Accounts Payable Turnover	0.16	0.00	0.15	0.12	0.09	0.08	0.12	0.07	0.00	0.00
Days Sales Outstanding (DSO)	72.25	61.58	69.49	61.12	60.14	73.39	74.66	61.33	79.49	77.13
Days Inventory Outstanding (DIO)	170.97	0.00	153.85	195.06	365.94	532.42	387.05	0.00	0.00	0.00
Days Payable Outstanding (DPO)	2,213.84	0.00	2,488.25	2,997.36	3,867.78	4,323.38	2,947.73	4,992.33	0.00	0.00
Cash Conversion Cycle (CCC)	-1,970.63	61.58	-2,264.91	-2,741.18	-3,441.70	-3,717.57	-2,486.02	-4,931.01	79.49	77.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1,952	-1,411	-186	-341	-313	222	276	110	-14	-21
Invested Capital Turnover	-0.48	-1.17	-2.65	-1.65	-8.38	1.23	1.37	4.04	-4.73	-1.94
Increase / (Decrease) in Invested Capital	-541	-1,225	154	-28	-534	-55	166	124	7.21	-4.30
Enterprise Value (EV)	2,627	1,487	2,905	2,474	3,370	2,587	1,657	646	241	863
Market Capitalization	3,481	2,080	2,744	2,816	4,164	2,960	1,732	692	374	1,110
Book Value per Share	($14.24)	($10.85)	($4.83)	$0.02	$7.06	$9.64	$6.95	$3.77	$3.48	$6.59
Tangible Book Value per Share	($16.85)	($16.97)	($15.79)	($11.40)	($4.63)	($3.22)	($8.57)	$0.57	$3.48	$6.59
Total Capital	-813	-534	225	433	791	908	504	301	218	318
Total Debt	285	284	572	431	309	314	153	145	98	92
Total Long-Term Debt	285	284	572	282	309	294	141	145	98	92
Net Debt	-854	-593	161	-342	-795	-373	-75	-46	-133	-247
Capital Expenditures (CapEx)	-22	28	32	28	18	14	7.10	3.10	1.78	2.72
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-355	-261	-123	-179	-149	-123	-62	-24	-20	-28
Debt-free Net Working Capital (DFNWC)	785	616	288	595	954	563	166	167	212	311
Net Working Capital (NWC)	785	616	288	445	954	543	154	167	212	311
Net Nonoperating Expense (NNE)	151	319	246	262	136	83	47	34	50	53
Net Nonoperating Obligations (NNO)	-854	-593	161	-342	-795	-373	-75	-46	-133	-247
Total Depreciation and Amortization (D&A)	64	236	132	71	86	31	26	19	5.48	5.46
Debt-free, Cash-free Net Working Capital to Revenue	-44.02%	-27.85%	-17.62%	-33.20%	-39.19%	-40.11%	-23.37%	-12.47%	-24.19%	-77.14%
Debt-free Net Working Capital to Revenue	97.24%	65.63%	41.15%	110.39%	250.66%	183.54%	62.60%	85.92%	255.92%	844.70%
Net Working Capital to Revenue	97.24%	65.63%	41.15%	82.63%	250.66%	177.02%	58.19%	85.92%	255.92%	844.70%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.73)	($8.37)	($7.79)	($7.43)	($6.64)	($4.27)	($2.75)	($2.02)	($4.17)	($5.07)
Adjusted Weighted Average Basic Shares Outstanding	76.85M	74.84M	71.73M	70.47M	70.32M	62.63M	58.40M	41.80M	34.56M	34.27M
Adjusted Diluted Earnings per Share	($4.73)	($8.37)	($7.79)	($7.43)	($6.64)	($4.27)	($2.75)	($2.02)	($4.17)	($5.07)
Adjusted Weighted Average Diluted Shares Outstanding	76.85M	74.84M	71.73M	70.47M	70.32M	62.63M	58.40M	41.80M	34.56M	34.27M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($6.64)	($4.27)	($2.75)	($2.02)	($4.17)	($5.07)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.87M	76.61M	73.82M	71.36M	66.03M	58.86M	46.58M	39.18M	34.04M	33.63M
Normalized Net Operating Profit after Tax (NOPAT)	-100	-155	-290	-262	-302	-169	-81	-45	-92	-117
Normalized NOPAT Margin	-12.34%	-16.55%	-41.47%	-48.67%	-79.38%	-54.99%	-30.59%	-23.15%	-111.77%	-318.20%
Pre Tax Income Margin	-45.01%	-74.23%	-84.07%	-96.24%	-105.82%	-78.16%	-48.39%	-39.95%	-171.14%	-462.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-3.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-2.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-3.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-2.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	459.73%	-30.58%	0.11%	-12.68%	-4.66%	83.41%	-9.47%	29.17%	48.17%	1.32%	56.50%
EBITDA Growth	11,817.45%	-243.77%	30.68%	75.57%	112.61%	182.40%	-6.44%	-62.32%	8.81%	-31.65%	23.61%
EBIT Growth	2,297.62%	-719.58%	59.27%	79.70%	59.26%	115.00%	-30.19%	-64.19%	-9.44%	-42.28%	4.94%
NOPAT Growth	2,941.90%	-2,890.19%	53.87%	80.81%	61.35%	102.91%	-73.29%	-126.87%	-35.94%	-136.45%	26.74%
Net Income Growth	1,046.28%	57.71%	19.79%	50.13%	34.10%	8.83%	-21.64%	-30.77%	-9.65%	-19.28%	18.19%
EPS Growth	936.67%	58.94%	21.02%	51.50%	36.17%	11.91%	-15.03%	-24.88%	-5.62%	-15.76%	19.05%
Operating Cash Flow Growth	1,129.64%	70.08%	-430.28%	-406.04%	339.94%	39.57%	61.84%	74.44%	69.72%	-141.09%	25.68%
Free Cash Flow Firm Growth	3.61%	-65.21%	1,652.56%	2,562.21%	921.87%	517.10%	152.41%	55.51%	-96.59%	-840.63%	-144.55%
Invested Capital Growth	-28.98%	-38.36%	-354.23%	-419.10%	-769.88%	-658.36%	-68.73%	-34.92%	30.31%	45.35%	29.96%
Revenue Q/Q Growth	451.71%	8.33%	5.40%	-11.14%	-31.57%	56.20%	-8.06%	-2.98%	31.64%	-22.90%	31.17%
EBITDA Q/Q Growth	750.20%	-183.63%	-37.47%	-570.07%	-92.16%	236.77%	51.56%	-142.71%	48.75%	-76.67%	26.13%
EBIT Q/Q Growth	727.80%	-172.32%	-33.47%	3.69%	-277.00%	117.90%	33.47%	-93.26%	34.83%	-55.36%	16.09%
NOPAT Q/Q Growth	895.45%	-197.91%	-35.54%	11.52%	-880.98%	104.93%	43.61%	-78.16%	41.29%	-193.81%	26.17%
Net Income Q/Q Growth	1,415.24%	38.22%	-7.54%	-8.30%	41.22%	-17.16%	33.14%	-43.12%	18.68%	-56.33%	28.12%
EPS Q/Q Growth	1,281.18%	38.85%	-7.75%	-7.50%	42.03%	-17.61%	33.83%	-41.49%	20.00%	-53.59%	28.17%
Operating Cash Flow Q/Q Growth	2,999.96%	61.03%	-7.75%	-200.98%	170.56%	-590.74%	-2.83%	52.12%	82.23%	-336.23%	31.13%
Free Cash Flow Firm Q/Q Growth	212.73%	-68.37%	-4.52%	9.71%	5.01%	1,493.23%	234.15%	63.38%	46.71%	-100.19%	-13.87%
Invested Capital Q/Q Growth	1.29%	-9.52%	0.34%	-19.71%	-5.89%	-259.56%	-13.90%	-100.60%	7.68%	20.00%	8.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.91%	73.07%	100.00%	100.00%	100.00%	111.84%	95.17%	94.05%	93.58%	85.12%	100.00%
EBITDA Margin	82.40%	-69.92%	-26.70%	-20.47%	3.87%	33.76%	-38.56%	-73.20%	-29.26%	-75.16%	-32.80%
Operating Margin	82.50%	-76.18%	-27.70%	-21.54%	-21.63%	1.90%	-60.11%	-98.01%	-53.37%	-119.67%	-31.40%
EBIT Margin	81.96%	-72.03%	-28.65%	-22.63%	-20.87%	8.07%	-70.42%	-97.31%	-48.85%	-98.67%	-48.97%
Profit (Net Income) Margin	73.68%	-30.91%	-54.20%	-53.12%	-43.58%	-50.74%	-67.64%	-93.02%	-63.05%	-102.08%	-50.35%
Tax Burden Percent	93.20%	69.57%	108.84%	115.68%	108.12%	99.20%	79.82%	83.75%	102.94%	90.09%	85.93%
Interest Burden Percent	96.46%	61.68%	173.80%	202.95%	193.10%	-633.76%	120.34%	114.14%	125.39%	114.83%	119.64%
Effective Tax Rate	6.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-110.19%	37.91%	52.54%	61.50%	85.72%	107.51%	142.96%	162.33%	208.43%	323.46%	871.29%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	65.37%	-32.28%	-16.64%	-12.52%	-11.40%	4.20%	-39.64%	-50.71%	-22.08%	-37.85%	-19.04%
Return on Assets (ROA)	58.77%	-13.85%	-31.47%	-29.40%	-23.79%	-26.43%	-38.07%	-48.47%	-28.51%	-39.15%	-19.57%
Return on Common Equity (ROCE)	-110.19%	37.91%	52.54%	61.50%	85.72%	107.51%	142.96%	162.33%	208.43%	323.46%	871.29%
Return on Equity Simple (ROE_SIMPLE)	-320.22%	0.00%	42.98%	48.92%	64.80%	0.00%	95.66%	106.69%	124.85%	0.00%	234.19%
Net Operating Profit after Tax (NOPAT)	904	-114	-38	-28	-32	4.07	-83	-147	-82	-140	-48
NOPAT Margin	76.88%	-53.32%	-19.39%	-15.08%	-15.14%	1.33%	-42.08%	-68.60%	-37.36%	-83.77%	-21.98%
Net Nonoperating Expense Percent (NNEP)	-3.22%	6.61%	-30.45%	-24.76%	-38.00%	-74.10%	36.86%	64.64%	87.19%	-33.88%	-27.82%
Return On Investment Capital (ROIC_SIMPLE)	904.64%	13.99%	-	-	-	-0.76%	-	-	-	-62.43%	-
Cost of Revenue to Revenue	1.09%	26.93%	0.00%	0.00%	0.00%	-11.84%	4.83%	5.95%	6.42%	14.88%	0.00%
SG&A Expenses to Revenue	6.88%	39.73%	37.33%	37.22%	34.87%	24.85%	41.15%	41.37%	39.44%	55.38%	36.90%
R&D to Revenue	9.27%	58.53%	82.02%	70.79%	55.27%	39.52%	83.54%	86.94%	88.54%	112.71%	76.21%
Operating Expenses to Revenue	16.41%	149.25%	127.70%	121.54%	121.63%	109.95%	155.28%	192.05%	146.95%	204.79%	131.40%
Earnings before Interest and Taxes (EBIT)	964	-154	-56	-42	-44	25	-138	-208	-108	-165	-106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	969	-149	-53	-38	8.13	104	-76	-156	-64	-126	-71
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.27	4.32	3.17	2.60	2.40	2.22	2.12	3.69	4.64	3.93	5.16
Price to Earnings (P/E)	6.76	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	14.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.28	3.26	2.36	1.71	1.76	1.59	2.46	3.97	5.01	4.16	5.15
Enterprise Value to EBITDA (EV/EBITDA)	3.12	0.00	101.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	3.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	3.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	3.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	2.10	7.97	1.64	1.18	1.53	1.62	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.54	-0.26	-0.27	-0.29	-0.32	-0.35	-0.85	-0.99	-1.25	-1.65	-1.25
Long-Term Debt to Equity	-1.54	-0.26	-0.27	-0.29	-0.32	-0.35	-0.85	-0.99	-1.25	-1.65	-1.25
Financial Leverage	2.17	0.75	0.26	0.37	0.23	0.37	-0.30	-0.21	-0.24	0.52	3.63
Leverage Ratio	-4.12	-1.88	-1.80	-2.09	-2.51	-3.09	-3.16	-4.13	-6.22	-10.54	-29.38
Compound Leverage Factor	-3.97	-1.16	-3.13	-4.24	-4.86	19.58	-3.80	-4.71	-7.80	-12.11	-35.15
Debt to Total Capital	285.85%	-35.12%	-37.06%	-40.96%	-46.69%	-53.19%	-587.05%	-8,643.67%	499.51%	254.51%	506.31%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	285.85%	-35.12%	-37.06%	-40.96%	-46.69%	-53.19%	-587.05%	-8,643.67%	499.51%	254.51%	506.31%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-185.85%	135.12%	137.06%	140.96%	146.69%	153.19%	687.05%	8,743.67%	-399.51%	-154.51%	-406.31%
Debt to EBITDA	0.39	-1.23	13.56	-128.12	-2.36	-1.47	-1.36	-1.37	-1.60	-1.57	-0.85
Net Debt to EBITDA	-2.39	3.69	-34.63	363.69	4.98	3.07	-0.66	-0.56	-0.80	-0.44	0.02
Long-Term Debt to EBITDA	0.39	-1.23	13.56	-128.12	-2.36	-1.47	-1.36	-1.37	-1.60	-1.57	-0.85
Debt to NOPAT	0.44	-1.35	-3.03	-2.05	-1.11	-0.92	-1.27	-1.37	-1.71	-1.83	-1.22
Net Debt to NOPAT	-2.67	4.03	7.74	5.83	2.33	1.93	-0.62	-0.56	-0.85	-0.51	0.02
Long-Term Debt to NOPAT	0.44	-1.35	-3.03	-2.05	-1.11	-0.92	-1.27	-1.37	-1.71	-1.83	-1.22
Altman Z-Score	2.03	-1.52	-1.31	-1.19	-1.31	-1.04	-2.63	-1.99	-1.01	-1.09	-0.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.89	2.35	2.10	2.23	2.03	2.02	1.10	1.24	1.39	1.71	1.23
Quick Ratio	3.76	2.23	1.99	2.10	1.88	1.72	0.94	1.08	1.11	1.39	0.98
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,337	428	1,352	1,416	1,291	1,229	77	-58	-157	-295	-147
Operating Cash Flow to CapEx	52,605.99%	-796.50%	-15,276.19%	0.00%	738.02%	-1,801.80%	-228.39%	-226.10%	-287.16%	-1,924.88%	-706.89%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	8.94	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.73	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.77	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.80	0.45	0.58	0.55	0.55	0.52	0.56	0.52	0.45	0.38	0.39
Accounts Receivable Turnover	8.69	5.05	4.93	4.94	4.64	5.93	5.50	5.22	4.49	5.25	6.30
Inventory Turnover	2.15	2.13	0.82	1.21	1.81	0.00	2.42	2.20	2.32	2.37	2.40
Fixed Asset Turnover	23.29	10.90	12.15	12.16	10.77	11.75	10.51	11.14	11.12	11.17	12.30
Accounts Payable Turnover	0.17	0.16	0.08	0.11	0.15	0.00	0.18	0.15	0.17	0.15	0.13
Days Sales Outstanding (DSO)	42.02	72.25	74.10	73.91	78.61	61.58	66.35	69.87	81.28	69.49	57.92
Days Inventory Outstanding (DIO)	170.05	170.97	447.65	301.77	201.57	0.00	150.61	165.73	157.17	153.85	152.30
Days Payable Outstanding (DPO)	2,132.45	2,213.84	4,431.68	3,296.17	2,356.75	0.00	2,085.12	2,430.14	2,168.89	2,488.25	2,911.53
Cash Conversion Cycle (CCC)	-1,920.38	-1,970.63	-3,909.93	-2,920.50	-2,076.57	61.58	-1,868.17	-2,194.54	-1,930.43	-2,264.91	-2,701.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1,927	-1,952	-1,783	-1,789	-1,494	-1,411	-392	-345	-172	-186	-233
Invested Capital Turnover	-1.04	-0.48	-0.83	-0.84	-1.11	-1.17	-2.55	-2.73	-3.68	-2.65	-2.47
Increase / (Decrease) in Invested Capital	-433	-541	-1,390	-1,444	-1,322	-1,225	-160	-89	75	154	99
Enterprise Value (EV)	2,278	2,627	2,126	1,537	1,628	1,487	1,967	3,252	3,861	2,905	3,586
Market Capitalization	4,019	3,481	2,854	2,345	2,229	2,080	1,688	3,017	3,576	2,744	3,591
Book Value per Share	($2.36)	($14.24)	($13.71)	($12.78)	($11.67)	($10.85)	($8.90)	($7.81)	($6.21)	($4.83)	($3.17)
Tangible Book Value per Share	($4.90)	($16.85)	($19.07)	($18.15)	($17.05)	($16.97)	($15.61)	($15.01)	($16.63)	($15.79)	($14.80)
Total Capital	100	-813	-769	-695	-609	-534	-98	-6.63	115	225	56
Total Debt	286	285	285	285	285	284	573	573	572	572	283
Total Long-Term Debt	286	285	285	285	285	284	573	573	572	572	283
Net Debt	-1,741	-854	-728	-808	-600	-593	278	235	286	161	-5.68
Capital Expenditures (CapEx)	1.65	3.77	0.50	-7.38	9.59	5.57	6.36	6.25	10	8.62	5.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-306	-355	-343	-345	-291	-261	-247	-225	-115	-123	-191
Debt-free Net Working Capital (DFNWC)	1,721	785	671	748	594	616	48	113	172	288	97
Net Working Capital (NWC)	1,721	785	671	748	594	616	48	113	172	288	97
Net Nonoperating Expense (NNE)	38	-48	68	71	60	160	50	52	57	31	62
Net Nonoperating Obligations (NNO)	-1,741	-854	-728	-808	-600	-593	278	235	286	161	-5.68
Total Depreciation and Amortization (D&A)	5.21	4.49	3.83	4.02	52	79	63	52	43	39	35
Debt-free, Cash-free Net Working Capital to Revenue	-17.27%	-44.02%	-38.03%	-38.33%	-31.33%	-27.85%	-30.89%	-27.43%	-14.87%	-17.62%	-27.45%
Debt-free Net Working Capital to Revenue	97.08%	97.24%	74.48%	83.08%	64.06%	65.63%	6.04%	13.84%	22.29%	41.15%	13.95%
Net Working Capital to Revenue	97.08%	97.24%	74.48%	83.08%	64.06%	65.63%	6.04%	13.84%	22.29%	41.15%	13.95%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$11.09	($0.85)	($1.39)	($1.29)	($1.20)	($2.07)	($1.76)	($2.66)	($1.88)	($2.35)	($1.53)
Adjusted Weighted Average Basic Shares Outstanding	78.12M	76.85M	76.93M	76.73M	76.50M	74.84M	75.38M	74.73M	73.73M	71.73M	71.65M
Adjusted Diluted Earnings per Share	$10.04	($0.85)	($1.39)	($1.29)	($1.20)	($2.07)	($1.76)	($2.66)	($1.88)	($2.35)	($1.53)
Adjusted Weighted Average Diluted Shares Outstanding	86.39M	76.85M	76.93M	76.73M	76.50M	74.84M	75.38M	74.73M	73.73M	71.73M	71.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	79.26M	78.87M	77.13M	76.92M	76.70M	76.61M	75.46M	75.34M	74.19M	73.82M	71.88M
Normalized Net Operating Profit after Tax (NOPAT)	904	-114	-37	-27	-32	4.07	-83	5.78	-82	-140	-48
Normalized NOPAT Margin	76.89%	-53.32%	-18.73%	-14.42%	-15.14%	1.33%	-42.08%	2.70%	-37.36%	-83.77%	-21.98%
Pre Tax Income Margin	79.06%	-44.42%	-49.80%	-45.92%	-40.31%	-51.15%	-84.75%	-111.07%	-61.25%	-113.31%	-58.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.14	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About PTC Therapeutics' Financials

When does PTC Therapeutics's fiscal year end?

According to the most recent income statement we have on file, PTC Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has PTC Therapeutics' net income changed over the last 9 years?

PTC Therapeutics' net income appears to be on an upward trend, with a most recent value of -$363.30 million in 2024, rising from -$170.45 million in 2015. The previous period was -$626.60 million in 2023. View PTC Therapeutics' forecast to see where analysts expect PTC Therapeutics to go next.

What is PTC Therapeutics's operating income?

PTC Therapeutics's total operating income in 2024 was -$302.57 million, based on the following breakdown:

Total Gross Profit: $749.38 million
Total Operating Expenses: $1.05 billion

How has PTC Therapeutics revenue changed over the last 9 years?

Over the last 9 years, PTC Therapeutics' total revenue changed from $36.77 million in 2015 to $806.78 million in 2024, a change of 2,094.4%.

How much debt does PTC Therapeutics have?

PTC Therapeutics' total liabilities were at $2.80 billion at the end of 2024, a 3.3% increase from 2023, and a 1,912.6% increase since 2015.

How much cash does PTC Therapeutics have?

In the past 9 years, PTC Therapeutics' cash and equivalents has ranged from $0.00 in 2018 to $779.71 million in 2024, and is currently $779.71 million as of their latest financial filing in 2024.

How has PTC Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, PTC Therapeutics' book value per share changed from 6.59 in 2015 to -14.24 in 2024, a change of -315.9%.

Related Companies

This page (NASDAQ:PTCT) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Financials

Frequently Asked Questions About PTC Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Financials

Annual Income Statements for PTC Therapeutics

Quarterly Income Statements for PTC Therapeutics

Annual Cash Flow Statements for PTC Therapeutics

Quarterly Cash Flow Statements for PTC Therapeutics

Annual Balance Sheets for PTC Therapeutics

Quarterly Balance Sheets for PTC Therapeutics

Annual Metrics And Ratios for PTC Therapeutics

Quarterly Metrics And Ratios for PTC Therapeutics

Frequently Asked Questions About PTC Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools